In colorectal cancer, cervical cancer, melanoma, and esophageal cancer, the loss of TAP1 expression ranges from 10% to 80.4%, and the loss of TAP1 expression suggests poor prognosis in tumor patients [49–52]. Here, TAP1 is linked to melanoma.